You are here

Spectral Announces First Orders of Its Proprietary CRRT Machine

TORONTO, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX:EDT), a Phase III company developing the first treatment for patients with endotoxemic septic shock guided by a companion diagnostic, today announces that, following the execution of the previously announced distribution agreement for its proprietary continuous renal replacement therapy (CRRT) machine with a private U.S. company, Spectral is now ready to ship out the first order of machines and related disposable for a cumulative revenue of $120,000 CAD. A second order in excess of $450,000 CAD has been processed and will be ready for shipment in Q2.
Thursday, February 21, 2019 - 08:00